Research Paper Volume 12, Issue 20 pp 20254—20267

Development and validation of an immune and stromal prognostic signature in uveal melanoma to guide clinical therapy

class="figure-viewer-img"

Figure 2. Kaplan-Meier survival analysis and Gene set variation analysis (GSVA) of high vs. low immune scores/stromal scores groups. (A, B) Overall survival among patients with uveal melanoma (UM) based on their immune and stromal scores; (C, D) Differential pathway activities between high and low immune and stromal scores groups, the same pathways are marked in red in the immune and stromal groups. Hazard ratios (HRs) and 95% CIs are for high vs low immune and stromal risk. The log-rank test was used to calculate P values in comparing risk groups.